Celyad to begin Phase Ib trial of NKR-2 CAR-T to treat seven cancer indications

Belgium-based biopharmaceutical company Celyad has secured the US Food and Drug Administration (FDA) approval to begin the Phase Ib THINK trial of NKR-2 CAR-T cells for the treatment of five solid cancers and two hematological malignancies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news